Evidence map›Paper›PMID 39981495›Full record

ArticleCureus2025

Lung Adenocarcinoma Presenting With Elevated Serum Carbohydrate Antigen 19-9 Levels: A Case Report.

Mónica Lopes, Vera Figueiredo, Ana Mendes, Marta Amaral, José Delgado Alves

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mónica LopesDepartment of Internal Medicine IV, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Vera FigueiredoDepartment of Pulmonology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Ana MendesDepartment of Oncology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Marta AmaralDepartment of Internal Medicine IV, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
José Delgado AlvesDepartment of Internal Medicine IV, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker usually used for the diagnosis and follow-up of pancreatic, gastric, and hepatobiliary malignancies. However, it has a low specificity and can be elevated in a wide array of other conditions. CA 19-9 elevation in lung tumors seems to be associated with the worst prognosis, but its role in this condition is not fully established yet. We present the case of a 78-year-old woman with mild consumptive symptoms, consisting of unselective anorexia and weight loss, and isolated high levels of CA 19-9. Hepatobiliary and gastrointestinal lesions were excluded, and a suspicious lesion was found in the right lung. A biopsy, which was only possible several months after presentation due to the location and small dimensions of the lesion, confirmed the diagnosis of lung adenocarcinoma. After an initial indolent course, the patient evolved with disease progression and is currently under treatment with palliative chemotherapy. This case illustrates the thorough investigation performed to clarify the elevation of a tumor biomarker measured in a pauci-symptomatic patient, which led to the identification of a rare and unsuspected etiology of high levels of CA 19-9.

Indexed as

cancer antigen 19-9elevated ca 19-9lung cancer with gastrointestinal featuresmetastatic non-small cell lung cancertumor biomarkers

Identifiers

PMID39981495
PMCPMC11841819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.